Twitter bird sign sells for nearly $35,000 at auction
Tuberculosis cases in the US rose to their highest levels in more than a dozen years
Trump’s executive order to dismantle the Education Department was inspired by the Heritage Foundation’s decades-long disapproval of the agency
Panama reopens talks about the future of a controversial copper mine, but opposition remains
Andrew Tate en route to Romania to meet legal obligations pending trafficking probe
Serbia deputy prime minister says Russian spies help put down protests
New Yorkers scramble for free eggs
Kyan Evans and favored No. 12 seed Colorado State beat short-handed Memphis 78-70 in March Madness
Car show organized in Whitman, Massachusetts, for an 11-year-old boy battling cancer
(Reuters) - AstraZeneca has warned it could relocate its vaccine manufacturing site from the UK to the United States as talks with the new Labour government over plans to cut state aid have become deadlocked, the Financial Times reported on Thursday.
British finance minister Rachel Reeves wants to reduce state provisions to the company's vaccine centre, which will cut the pledge made by the previous administration from about 90 million pounds to 40 million pounds, the report said, citing sources.
The previous offer included up to 70 million in grants to develop a facility in Speke, Liverpool and 20 million pounds in research and development support from the UK Health Security Agency, the Financial Times report said.
Manufacturing could take place in India, where the company has produced vaccines in the past, people briefed on the discussions told the newspaper.
An AztraZeneca spokesperson said: "We are committed to pursuing the opportunity at Speke and are in constructive discussions with the UK government."
"We have no idea where the comments in some media come from and they do not seem to be based on facts. As an example, there are no discussions in the US or India," the spokesperson said.
"We are in positive discussions with AstraZeneca to support the delivery of this planned investment in Speke," a UK Treasury spokesperson said.
The Sunak administration in March planned to invest 650 million pounds in the Anglo-Swedish drugmaker to boost research, development and manufacturing of vaccines.
(Reporting by Urvi Dugar in Bengaluru; Additional reporting by Chandni Shah and Rhea Rose Abraham in Bengaluru; Editing by Arun Koyyur and Jane Merriman)
